APA (7th ed.) Citation

Pivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., . . . Fallowfield, L. (2013). Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): An open-label randomised study. The lancet oncology, 14(10), 962-970. https://doi.org/10.1016/S1470-2045(13)70383-8

Chicago Style (17th ed.) Citation

Pivot, Xavier, et al. "Preference for Subcutaneous or Intravenous Administration of Trastuzumab in Patients with HER2-positive Early Breast Cancer (PrefHer): An Open-label Randomised Study." The Lancet Oncology 14, no. 10 (2013): 962-970. https://doi.org/10.1016/S1470-2045(13)70383-8.

MLA (9th ed.) Citation

Pivot, Xavier, et al. "Preference for Subcutaneous or Intravenous Administration of Trastuzumab in Patients with HER2-positive Early Breast Cancer (PrefHer): An Open-label Randomised Study." The Lancet Oncology, vol. 14, no. 10, 2013, pp. 962-970, https://doi.org/10.1016/S1470-2045(13)70383-8.